Halozyme Therapeutics

ISIN US40637H1095

 | 

WKN A0DLHS

Marktkapitalisatie (in EUR)
6,465 m
Land
United States
Sector
Healthcare
Dividendrendement
0.00%
 

Overzicht

Beschrijving

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Toon meer Toon minder
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR 6,465 m
WPA, EUR 2.21
KBV 154.1
K/W 25.0
Dividendrendement 0.00%

Income statement (2025)

Omzet, EUR 1,238 m
Netto-inkomen, EUR 281 m
Winstmarge 22.69%

What ETF is Halozyme Therapeutics in?

There are 4 ETFs which contain Halozyme Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Halozyme Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weging Investeringsfocus Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.61%
Equity
United States
Health Care
Biotech
46
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
508
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
25
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.13%
Equity
United States
Small Cap
204
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.

Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.